This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

ASCO® 2024 Insights: "NETTER-2 Study - Safety & TTR of [177Lu]Lu-DOTATATE in Pts With Newly Diagnosed Advanced Grade 2 & 3, Well-Differentiated Gastroenteropancreatic NETs"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Pamela Kunz
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Pamela Kunz
27 views
June 12, 2024

Chapters

NETTER-2 Study Overview & Key Differences

00:00

Safety & Time to Response in NETTER-2

01:54

0 Comments
Login to view comments. Click here to Login

2024 ASCO® Annual Meeting Insights Hub: GI Videos

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Botensilimab + Balstilimab in Microsatell…

Feat. A. Bullock
12:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreat…

Feat. J. Knox
12:29
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

Feat. C. Eng
View All

Related Content

AUTOPLAY
North American Neuroendocrine Tumor Society

Minneapolis Regional NET Education Event

Sat, Sep 21, 2024
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
24:58
Integrity CE

Neuroendocrine Tumors: Management and Updates

Feat. R. Iyer
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
24:56
Florida Gastroenterologic Society

Neuroendocrine Tumors in the GI Tract

Feat. A. Luthra
15:20
Integrity CE

Sequencing Systemic Treatments for Well-Differentiated NETs

Feat. J. Strosberg
06:03
Total Health

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Feat. A. Grothey
20:30
Total Health

Neuroendocrine Cancers: Background, Diagnosis, and Current Treatment

Feat. R. Lentz
15:24
Horizon CME

MRD in GI Malignancies: Current Clinical Utility of ctDNA

Feat. A. Scott
13:06
Yale Cancer Center

NETs 101 and Overview of Medical Management

Feat. P. Kunz
05:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "212Pb-DOTAMTATE, a Targeted Alpha Therapy…

Feat. J. Strosberg
13:47
Oncology Data Advisor

New Developments in Neuroendocrine Tumor Treatment

Feat. S. Kareff, A. Chauhan
14:37
Fred Hutchinson Cancer Center

SWOG S2012: 1L Chemo +/- Atezolizumab in Advanced Extrapulmonary Neu…

Feat. D. Zhen
16:31
Integrity CE

Debates in NET Treatment: Surgery vs. IR for Liver-Limited Disease

Feat. E. Liu
27:34
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Medical Oncology Updates in NETs

Feat. P. Kunz
19:29
Integrity CE

Metastatic Grade 2 NET: Case Presentation and Panel Discussion

Feat. A. De Jesus-Acosta, L. Bjork Solnes, J. Strosberg, E. Liu, R. Lidell
22:31
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Controversies in Management of Neuroendocrine Tumors

Feat. T. Pawlik
38:10
McMaster University Department of Medicine

Carcinoid Syndrome: Relationship to NETs, Clinical Overview, and Tre…

Feat. U. Kharad, J. Su, M. Smith-Uffen
21:20
University of Miami Sylvester Comprehensive Cancer Center

Role of Precision Medicine in the Treatment of Neuroendocrine Neopla…

Feat. A. Chauhan
15:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NETTER-2 Study - Efficacy and Safety of 1…

Feat. P. Philip
11:41
Northwell Health

Neuroendocrine Cancers of the Lung

Feat. N. Seetharamu